Skip to main content

Table 2 Cohort characteristics at enrolment

From: Testing the regulatory framework in South Africa – a single-blind randomized pilot trial of commercial probiotic supplementation to standard therapy in women with bacterial vaginosis

 

SOC n = 12

Intervention n = 18

Age participant [years, median (IQR)]

23 (21–34)

22 (20–26)

Self-identified race [% (n)]

 Black

58.3 (7)

72.2 (13)

 Coloured

25.0 (3)

16.7 (3)

 White

16.7 (2)

11.1 (2)

Age menarche [years, median (IQR)]

12 (11–15)

14 (13–16)

Marital Status [% (n)]

 Single

83.3 (10)

88.9 (16)

 Married

8.3 (1)

 Separated/Divorced

8.3 (1)

11.1 (2)

Pregnancies and contraception [% (n)]

 Ever been pregnant

25.0 (3)

27.8 (5)

 Currently using hormonal contraception

33.3 (4)

38.9 (7)

Reported current smoking [% (n)]

50.0 (6)

44.4 (8)

Sexual risk behaviour and sexual health

 Age of sexual debut [median (IQR)]

18 (17–18)

17 (16–19)

 Number of lifetime partners [median (IQR)]

5 (3–8)

4 (3–8)

 Oral sex during last 6 months [% (n)]

58.3 (7)

77.8 (14)

 Regular condom use during last 6 months [% (n)]

66.7 (8)

55.6 (10)

 Ever been diagnosed or treated for a STI [% (n)]

8.3 (1)

16.7 (3)

 Partner or participant STI in last 6 month [% (n)]

16.7 (3)

 Long-term history of vaginal discharge [% (n)]

83.3 (10)

100 (18)

Vaginal product use [% (n)]

 Use of medicine from doctor/nurse

58.3 (7)

72.2 (13)

 Use of tampon

25.0 (3)

16.7 (3)

 Cleansing with fingers

16.7 (2)

11.1 (2)

 Cleansing with water

25.0 (3)

33.3 (6)

 Douching to clean vagina

16.7 (3)

 Cleansing with soap

8.3 (1)

5.6 (1)